Antengene presents results of phase 1b touch trial of selinexor for the treatment of t and nk-cell lymphoma at the 2021 american society of hematology (ash) annual meeting

Shanghai and hong kong, dec. 14, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it presented results of the company-sponsored, open-label phase 1b touch study with selinexor (atg-010) for the treatment of relapsed/refractory (rr) t and nk-cell lymphoma, in a poster presentation ( nct04425070, see details below) at the 2021 ash annual meeting, being held from december 11-14, 2021, both in atlanta, georgia and virtually. https://www.hematology.org/meetings/annual-meeting eligible patients (pts) for touch were rr t and nk-cell lymphoma cases with at least one prior systemic therapy.
KPTI Ratings Summary
KPTI Quant Ranking